Asset | Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Orphan Diseases | ||||||
TPN-101 | Progressive Supranuclear Palsy (PSP) | |||||
TPN-101 | Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Dementia (FTD) | |||||
TPN-101 | Aicardi-Goutières Syndrome (AGS) | Phase 2a late 2022 | ||||
New Indications | ||||||
TPN-101 | Alzheimer's Disease & Others | In planning | ||||
Novel NRTIs | To be determined | |||||
Novel PKRi | Disorders of cognition |
AFTD Website FTD Registry NEALS Website |
NEALS Video: Dr. Merit Cudkowicz National ALS Registry ClinicalTrials.gov |
![]() Eckard Weber, MD Chief Executive Officer |
![]() Michael Cordingley, PhD Chief Scientific Officer |
![]() Andrew Satlin, MD Chief Medical Officer |
![]() Debra Liebert Chief Development Officer |
![]() Lynne Rollins Chief Financial Officer |
![]() Walter Bee, PhD SVP Preclinical & Biomarker Development |
![]() Priya Jambhekar Head, Regulatory |
![]() Mark Mugerditchian VP Manufacturing |
![]() Jay Soto Head, Clinical Operations |
John Sedivy, PhD Chair
Brown University
Kathy Burns, MD PhD
DFCI, Harvard Med School
George Church, PhD
Harvard University
Josh Dubnau, PhD
SUNY at Stony Brook
Rusty Gage, PhD
Salk Institute
Molly Hammel, PhD
Cold Spring Harbor Lab
Murali Doraiswamy, MD Chair
Duke University
Adam Boxer, MD
UCSF
Yanick Crow, MD, PhD
Univ. Edinburgh (AGS)
Merit Cudkowicz, MD
MGH
John Ravits, MD
UCSD
![]() Dennis Podlesak Chair |
![]() Brent Ahrens Director |
![]() Bill Harrington, MD Director |
![]() Daniel Hetu, MD Director |
![]() Keith Katkin Director |
![]() John Pacifico Director |
![]() BT Slingsby, MD Director |
![]() Eckard Weber, MD Director and Chief Executive Officer |